Please use this identifier to cite or link to this item:
Title: The HPA axis and GABA-Glutamate Systems as Potential Antidepressant Targets in Prostate Cancer
Contributor(s): Sharpley, Chris  (author)orcid ; Christie, David R H  (author)
Publication Date: 2011
DOI: 10.2174/1876822901104010001
Handle Link:
Abstract: A common treatment for Prostate Cancer includes androgen-deprivation for a period of months prior to radiation or surgery. Some data suggest that this may exacerbate the already elevated depression levels of these patients, arguing for concomitant application of antidepressant therapy. However, the various waves of antidepressants developed in the last 40 years have shown only arguable specific efficacy over placebo, plus significant side-effects which may hinder treatment decision-making and compliance. This paper outlines two emerging and potential pathways for development of new pharmacological agents for depression that hold promise of helping patients to reduce their depressive symptomatology.
Publication Type: Journal Article
Source of Publication: Open Prostate Cancer Journal, v.4, p. 1-5
Publisher: Bentham Open
Place of Publication: The Netherlands
ISSN: 1876-8229
Field of Research (FOR): 110319 Psychiatry (incl Psychotherapy)
Socio-Economic Outcome Codes: 920199 Clinical Health (Organs, Diseases and Abnormal Conditions) not elsewhere classified
Peer Reviewed: Yes
HERDC Category Description: C1 Refereed Article in a Scholarly Journal
Statistics to Oct 2018: Visitors: 117
Views: 116
Downloads: 0
Appears in Collections:Journal Article

Files in This Item:
2 files
File Description SizeFormat 
Show full item record

Page view(s)

checked on Mar 5, 2019
Google Media

Google ScholarTM



Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.